KLBF – Focus on prescription drug product and innovation

KLBF – Focus on prescription drug product and innovation Kalbe Farma (KLBF) is focusing on strengthening its prescription drug division by innovating and collaborating to discover new products. They aim for moderate single-digit growth by year-end. They've introduced a new anemia drug called EFESA but expect it to take time to gain widespread adoption. In the 2H23, KLBF continue to strengthen the prescription drug division and innovate in preventive categories like herbal products, vitamins, and supplements. While KLBF net profit decreased to IDR1.52 tn (-6.6% yoy) in the 1H23, net sales increased to IDR15.17 tn (+9.4% yoy). (Source: Kontan)